Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	inositol 1,4,5-trisphosphate-gated calcium channel activity	ITPR1 ITPR2	6.70e-05	3	95	2	GO:0005220
GeneOntologyBiologicalProcess	negative regulation of macroautophagy	USP36 PIK3CA LZTS1 MTOR TSC2	5.42e-07	35	95	5	GO:0016242
GeneOntologyBiologicalProcess	anoikis	PIK3CA MTOR PDK4 NTRK2 TSC2	7.23e-07	37	95	5	GO:0043276
GeneOntologyBiologicalProcess	toll-like receptor 3 signaling pathway	COLEC12 TRAF6 TICAM1 TRIM3	1.21e-05	31	95	4	GO:0034138
GeneOntologyBiologicalProcess	regulation of calcium-mediated signaling	MTOR CAMTA1 ITGAL NFAT5 ITPR1 DYRK2	2.04e-05	121	95	6	GO:0050848
GeneOntologyBiologicalProcess	regulation of calcineurin-NFAT signaling cascade	MTOR CAMTA1 NFAT5 DYRK2	4.98e-05	44	95	4	GO:0070884
GeneOntologyBiologicalProcess	regulation of calcineurin-mediated signaling	MTOR CAMTA1 NFAT5 DYRK2	5.44e-05	45	95	4	GO:0106056
GeneOntologyBiologicalProcess	TORC2 signaling	PIK3CA MTOR SIK3	6.14e-05	17	95	3	GO:0038203
GeneOntologyBiologicalProcess	negative regulation of anoikis	PIK3CA PDK4 NTRK2	8.69e-05	19	95	3	GO:2000811
GeneOntologyBiologicalProcess	calcineurin-NFAT signaling cascade	MTOR CAMTA1 NFAT5 DYRK2	1.12e-04	54	95	4	GO:0033173
GeneOntologyBiologicalProcess	endolysosomal toll-like receptor signaling pathway	COLEC12 TRAF6 TICAM1 TRIM3	1.29e-04	56	95	4	GO:0140894
GeneOntologyBiologicalProcess	negative regulation of organelle organization	EVL PIK3CA MTOR PPFIA1 POT1 TMOD1 CDK5RAP2 TSC2 SMG6	1.41e-04	421	95	9	GO:0010639
GeneOntologyBiologicalProcess	calcineurin-mediated signaling	MTOR CAMTA1 NFAT5 DYRK2	1.48e-04	58	95	4	GO:0097720
GeneOntologyBiologicalProcess	regulation of GTPase activity	MTOR NTRK2 POT1 TSC2 AGAP7P AGAP4 AGAP6 EPHA4	1.59e-04	335	95	8	GO:0043087
GeneOntologyBiologicalProcess	negative regulation of autophagy	USP36 PIK3CA LZTS1 MTOR TSC2	1.70e-04	112	95	5	GO:0010507
GeneOntologyBiologicalProcess	process utilizing autophagic mechanism	USP36 TRAF6 SUPT20H PIK3CA LZTS1 MTOR ARHGAP26 TICAM1 TSC2 EIF2AK1 ITPR1	1.98e-04	650	95	11	GO:0061919
GeneOntologyBiologicalProcess	autophagy	USP36 TRAF6 SUPT20H PIK3CA LZTS1 MTOR ARHGAP26 TICAM1 TSC2 EIF2AK1 ITPR1	1.98e-04	650	95	11	GO:0006914
GeneOntologyBiologicalProcess	regulation of macroautophagy	USP36 PIK3CA LZTS1 MTOR TSC2 EIF2AK1	2.22e-04	186	95	6	GO:0016241
GeneOntologyBiologicalProcess	regulation of anoikis	PIK3CA PDK4 NTRK2	2.28e-04	26	95	3	GO:2000209
GeneOntologyBiologicalProcess	calcium-mediated signaling	MTOR CAMTA1 ITGAL NFAT5 ITPR1 DYRK2 ITPR2	2.31e-04	266	95	7	GO:0019722
GeneOntologyBiologicalProcess	negative regulation of calcium-mediated signaling	MTOR ITPR1 DYRK2	2.56e-04	27	95	3	GO:0050849
GeneOntologyBiologicalProcess	macroautophagy	USP36 TRAF6 PIK3CA LZTS1 MTOR ARHGAP26 TSC2 EIF2AK1	3.34e-04	374	95	8	GO:0016236
GeneOntologyBiologicalProcess	organelle disassembly	USP36 ARHGAP26 TSC2 EIF2AK1 GFM2 KLC1	3.64e-04	204	95	6	GO:1903008
GeneOntologyBiologicalProcess	mitophagy	USP36 ARHGAP26 TSC2 EIF2AK1	4.00e-04	75	95	4	GO:0000423
HumanPheno	Hemihypertrophy of lower limb	RASA1 PIK3CA	2.91e-05	2	28	2	HP:0100553
HumanPheno	Hypertrophy of the lower limb	RASA1 PIK3CA	2.91e-05	2	28	2	HP:0010496
HumanPheno	Hypertrophy of the upper limb	RASA1 PIK3CA	2.91e-05	2	28	2	HP:0010484
HumanPheno	Focal impaired awareness seizure	MTOR TICAM1 TSC2 CNOT1 KDM6A ITPR1	4.90e-05	126	28	6	HP:0002384
HumanPheno	Hemimegalencephaly	PIK3CA MTOR TSC2	5.20e-05	14	28	3	HP:0007206
HumanPheno	Focal cortical dysplasia	PIK3CA MTOR TSC2	6.48e-05	15	28	3	HP:0032046
HumanPheno	Hemihypsarrhythmia	PIK3CA MTOR	8.71e-05	3	28	2	HP:0011215
HumanPheno	Abnormal lymphatic vessel morphology	RASA1 PIK3CA TSC2	9.61e-05	17	28	3	HP:0100766
HumanPheno	Abnormal astrocyte morphology	PIK3CA MTOR TSC2 NUP54	1.02e-04	46	28	4	HP:0100707
HumanPheno	Astrocytosis	MTOR TSC2 NUP54	2.14e-04	22	28	3	HP:0002446
Domain	ARM-type_fold	IPO7 CEBPZ PIK3CA MTOR NBEAL2 MROH5 TSC2 HEATR5A ITPR1 ITPR2	7.96e-06	339	94	10	IPR016024
Domain	TPR-like_helical_dom	TRAPPC12 MTOR HELZ COPS3 CFAP70 KDM6A KLC1 SMG6	2.30e-05	233	94	8	IPR011990
Domain	InsP3_rcpt-bd	ITPR1 ITPR2	7.49e-05	3	94	2	IPR000493
Domain	-	TRAPPC12 MTOR HELZ CFAP70 KDM6A KLC1 SMG6	8.41e-05	207	94	7	1.25.40.10
Domain	Znf_FCS	PHC3 PHC2	2.48e-04	5	94	2	IPR012313
Domain	RIH_assoc	ITPR1 ITPR2	3.71e-04	6	94	2	PF08454
Domain	RIH_assoc-dom	ITPR1 ITPR2	3.71e-04	6	94	2	IPR013662
Domain	RIH_dom	ITPR1 ITPR2	3.71e-04	6	94	2	IPR000699
Domain	Ins145_P3_rcpt	ITPR1 ITPR2	3.71e-04	6	94	2	IPR014821
Domain	Ryanodine_recept-rel	ITPR1 ITPR2	3.71e-04	6	94	2	IPR015925
Domain	ZF_FCS	PHC3 PHC2	3.71e-04	6	94	2	PS51024
Domain	-	ITPR1 ITPR2	3.71e-04	6	94	2	1.25.10.30
Domain	RYDR_ITPR	ITPR1 ITPR2	3.71e-04	6	94	2	PF01365
Domain	Ins145_P3_rec	ITPR1 ITPR2	3.71e-04	6	94	2	PF08709
Domain	ArfGap	AGAP7P AGAP4 AGAP6	4.10e-04	29	94	3	SM00105
Domain	ArfGap	AGAP7P AGAP4 AGAP6	4.10e-04	29	94	3	PF01412
Domain	ARFGAP	AGAP7P AGAP4 AGAP6	4.10e-04	29	94	3	PS50115
Domain	ArfGAP	AGAP7P AGAP4 AGAP6	4.10e-04	29	94	3	IPR001164
Domain	Ski_Sno	DACH2 DACH1	5.18e-04	7	94	2	PF02437
Domain	-	DACH2 DACH1	5.18e-04	7	94	2	3.10.260.20
Domain	Transform_Ski	DACH2 DACH1	5.18e-04	7	94	2	IPR003380
Domain	VWFA	ITGA11 MDN1 VWA8 ITGAL	7.80e-04	82	94	4	PS50234
Domain	VWA	ITGA11 MDN1 VWA8 ITGAL	8.54e-04	84	94	4	SM00327
Domain	SAM	PHC3 PPFIA1 PHC2 EPHA4	1.02e-03	88	94	4	SM00454
Domain	MIR	ITPR1 ITPR2	1.10e-03	10	94	2	PS50919
Domain	MIR	ITPR1 ITPR2	1.10e-03	10	94	2	PF02815
Domain	MIR	ITPR1 ITPR2	1.10e-03	10	94	2	SM00472
Domain	MIR_motif	ITPR1 ITPR2	1.10e-03	10	94	2	IPR016093
Domain	DNA-bd_dom_put	DACH2 DACH1	1.34e-03	11	94	2	IPR009061
Domain	SAM_DOMAIN	PHC3 PPFIA1 PHC2 EPHA4	1.35e-03	95	94	4	PS50105
Domain	SAM	PHC3 PPFIA1 PHC2 EPHA4	1.46e-03	97	94	4	IPR001660
Domain	VWF_A	ITGA11 MDN1 VWA8 ITGAL	1.57e-03	99	94	4	IPR002035
Domain	-	PHC3 PPFIA1 PHC2 EPHA4	2.02e-03	106	94	4	1.10.150.50
Domain	ATPase_dyneun-rel_AAA	MDN1 VWA8	2.19e-03	14	94	2	IPR011704
Domain	AAA_5	MDN1 VWA8	2.19e-03	14	94	2	PF07728
Domain	ARM-like	IPO7 MTOR NBEAL2 MROH5 TSC2 HEATR5A	2.43e-03	270	94	6	IPR011989
Domain	PI3/4_kinase_CS	PIK3CA MTOR	2.52e-03	15	94	2	IPR018936
Domain	VWA	ITGA11 VWA8 ITGAL	2.82e-03	56	94	3	PF00092
Domain	PH_DOMAIN	RASA1 ADRM1 ARHGAP26 AGAP7P AGAP4 AGAP6	2.86e-03	279	94	6	PS50003
Domain	-	PIK3CA MTOR	2.87e-03	16	94	2	1.10.1070.11
Domain	PI3Kc	PIK3CA MTOR	2.87e-03	16	94	2	SM00146
Domain	SAM/pointed	PHC3 PPFIA1 PHC2 EPHA4	2.89e-03	117	94	4	IPR013761
Domain	Integrin_alpha-2	ITGA11 ITGAL	3.64e-03	18	94	2	IPR013649
Domain	Integrin_alpha2	ITGA11 ITGAL	3.64e-03	18	94	2	PF08441
Domain	PI3/4_kinase_cat_dom	PIK3CA MTOR	3.64e-03	18	94	2	IPR000403
Domain	Integrin_alpha	ITGA11 ITGAL	3.64e-03	18	94	2	IPR000413
Domain	PI3_PI4_kinase	PIK3CA MTOR	3.64e-03	18	94	2	PF00454
Domain	PI3_4_KINASE_3	PIK3CA MTOR	3.64e-03	18	94	2	PS50290
Domain	PI3_4_KINASE_1	PIK3CA MTOR	3.64e-03	18	94	2	PS00915
Domain	PI3_4_KINASE_2	PIK3CA MTOR	3.64e-03	18	94	2	PS00916
Domain	INTEGRIN_ALPHA	ITGA11 ITGAL	3.64e-03	18	94	2	PS00242
Domain	Int_alpha_beta-p	ITGA11 ITGAL	4.05e-03	19	94	2	IPR013519
Domain	Int_alpha	ITGA11 ITGAL	4.05e-03	19	94	2	SM00191
Domain	TPR	TRAPPC12 CFAP70 KDM6A KLC1	4.10e-03	129	94	4	SM00028
Domain	TPR_repeat	TRAPPC12 CFAP70 KDM6A KLC1	4.57e-03	133	94	4	IPR019734
Domain	SAM_1	PHC3 PPFIA1 PHC2	4.88e-03	68	94	3	PF00536
Domain	UDPGT	UGT1A4 UGT1A5	4.95e-03	21	94	2	PF00201
Domain	UDPGT	UGT1A4 UGT1A5	4.95e-03	21	94	2	PS00375
Domain	UDP_glucos_trans	UGT1A4 UGT1A5	4.95e-03	21	94	2	IPR002213
Pathway	REACTOME_INTRACELLULAR_SIGNALING_BY_SECOND_MESSENGERS	PHC3 TRAF6 PIK3CA MTOR NTRK2 TSC2 TNRC6C PHC2 ITPR1 ITPR2	3.51e-06	313	71	10	M27867
Pathway	KEGG_MEDICUS_REFERENCE_IGF_IGF1R_PI3K_SIGNALING_PATHWAY	PIK3CA MTOR TSC2	3.38e-05	13	71	3	M47603
Pathway	KEGG_MEDICUS_REFERENCE_RELN_VLDLR_PI3K_SIGNALING_PATHWAY	PIK3CA MTOR TSC2	5.33e-05	15	71	3	M47663
Pathway	REACTOME_VEGFR2_MEDIATED_CELL_PROLIFERATION	RASA1 ITPR1 ITPR2	1.12e-04	19	71	3	M27423
Pathway	WP_SYNAPTIC_SIGNALING_ASSOCIATED_WITH_AUTISM_SPECTRUM_DISORDER	PIK3CA MTOR NTRK2 TSC2	1.14e-04	50	71	4	M39822
Pathway	BIOCARTA_MTOR_PATHWAY	PIK3CA MTOR TSC2	1.31e-04	20	71	3	MM1437
Pathway	WP_PI3KAKTMTOR_VITAMIN_D3_SIGNALING	PIK3CA MTOR TSC2	1.76e-04	22	71	3	M39345
Pathway	BIOCARTA_MTOR_PATHWAY	PIK3CA MTOR TSC2	1.76e-04	22	71	3	M16563
Pathway	REACTOME_SIGNALING_BY_VEGF	RASA1 PIK3CA MTOR ITPR1 ITPR2	1.92e-04	106	71	5	M27077
Pathway	PID_FAK_PATHWAY	RASA1 PIK3CA ARHGAP26 VCL	2.18e-04	59	71	4	M281
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_PRKN_TO_MGLUR1_SIGNALING_PATHWAY	ITPR1 ITPR2	2.48e-04	5	71	2	M49000
Pathway	WP_4HYDROXYTAMOXIFEN_DEXAMETHASONE_AND_RETINOIC_ACIDS_REGULATION_OF_P27_EXPRESSION	PIK3CA MTOR TSC2	2.60e-04	25	71	3	M39574
Pathway	WP_EFFECT_OF_OMEGA3_PUFA_ON_HUNTINGTONS_DISEASE_PATHWAYS	PIK3CA MTOR NTRK2 TSC2 ITPR1	3.29e-04	119	71	5	M48309
Pathway	WP_FRAGILE_X_SYNDROME	MTOR NTRK2 TSC2 EPHA4 ITPR1	3.55e-04	121	71	5	M39804
Pathway	KEGG_MEDICUS_REFERENCE_CA2_PLCD_ITPR_SIGNALING_PATHWAY	ITPR1 ITPR2	3.70e-04	6	71	2	M47960
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_PI3K_TO_PI3K_SIGNALING_PATHWAY	PIK3CA MTOR	5.17e-04	7	71	2	M47407
Pathway	REACTOME_ACTIVATED_NTRK2_SIGNALS_THROUGH_PI3K	PIK3CA NTRK2	5.17e-04	7	71	2	M27910
Pathway	WP_PI3KAKTMTOR_SIGNALING_AND_THERAPEUTIC_OPPORTUNITIES_IN_PROSTATE_CANCER	PIK3CA MTOR TSC2	5.47e-04	32	71	3	M39445
Pathway	WP_BDNFTRKB_SIGNALING	MTOR NTRK2 TSC2	5.99e-04	33	71	3	M39532
Pathway	KEGG_MEDICUS_VARIANT_AMPLIFIED_PDGFR_TO_PI3K_SIGNALING_PATHWAY	PIK3CA MTOR	6.87e-04	8	71	2	M47399
Pathway	KEGG_MEDICUS_VARIANT_AMPLIFIED_EGFR_TO_PI3K_SIGNALING_PATHWAY	PIK3CA MTOR	6.87e-04	8	71	2	M47394
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_RET_TO_PI3K_SIGNALING_PATHWAY	PIK3CA MTOR	6.87e-04	8	71	2	M47715
Pathway	SIG_PIP3_SIGNALING_IN_B_LYMPHOCYTES	PIK3CA ITPR1 ITPR2	7.76e-04	36	71	3	M1315
Pathway	WP_BRAINDERIVED_NEUROTROPHIC_FACTOR_BDNF_SIGNALING	TRAF6 MTOR NTRK2 CRTC1 TSC2	7.86e-04	144	71	5	M39691
Pathway	KEGG_MEDICUS_VARIANT_AMPLIFIED_FGFR_TO_PI3K_SIGNALING_PATHWAY	PIK3CA MTOR	8.80e-04	9	71	2	M47397
Pathway	KEGG_MEDICUS_REFERENCE_BCR_PLCG_ITPR_SIGNALING_PATHWAY	ITPR1 ITPR2	8.80e-04	9	71	2	M47852
Pathway	KEGG_MEDICUS_VARIANT_AMPLIFIED_MET_TO_PI3K_SIGNALING_PATHWAY	PIK3CA MTOR	8.80e-04	9	71	2	M47490
Pathway	KEGG_MEDICUS_REFERENCE_TGFA_EGFR_PI3K_SIGNALING_PATHWAY	PIK3CA MTOR	8.80e-04	9	71	2	M47481
Pathway	KEGG_MEDICUS_VARIANT_EGFR_OVEREXPRESSION_TO_PI3K_SIGNALING_PATHWAY	PIK3CA MTOR	1.10e-03	10	71	2	M47400
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_SPTBN2_TO_MGLUR1_TRPC3_SIGNALING_PATHWAY	ITPR1 ITPR2	1.10e-03	10	71	2	M47661
Pathway	KEGG_MEDICUS_REFERENCE_TLR3_NFKB_SIGNALING_PATHWAY	TRAF6 TICAM1	1.10e-03	10	71	2	M47601
Pathway	WP_THYROID_HORMONES_PRODUCTION_AND_PERIPHERAL_DOWNSTREAM_SIGNALING_EFFECTS	PIK3CA MTOR TSC2 ITPR2	1.23e-03	93	71	4	M39791
Pathway	REACTOME_SIGNALING_BY_ALK_IN_CANCER	PIK3CA TNRC6C VCL KLC1	1.23e-03	93	71	4	M42521
Pathway	WP_FOCAL_ADHESION_PI3KAKTMTOR_SIGNALING_PATHWAY	ITGA11 PIK3CA MTOR LAMA5 TSC2 ITGAL IFNA14	1.24e-03	326	71	7	MM15917
Pathway	PID_CXCR3_PATHWAY	PIK3CA MTOR ITGAL	1.31e-03	43	71	3	M222
Pathway	WP_FIBRIN_COMPLEMENT_RECEPTOR_3_SIGNALING	TRAF6 PIK3CA TICAM1	1.31e-03	43	71	3	M39744
Pathway	KEGG_MEDICUS_REFERENCE_KITLG_KIT_PI3K_SIGNALING_PATHWAY	PIK3CA MTOR	1.34e-03	11	71	2	M47403
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_PRKCG_TO_MGLUR1_TRPC3_SIGNALING_PATHWAY	ITPR1 ITPR2	1.34e-03	11	71	2	M49033
Pathway	REACTOME_TICAM1_TRAF6_DEPENDENT_INDUCTION_OF_TAK1_COMPLEX	TRAF6 TICAM1	1.34e-03	11	71	2	M27885
Pathway	REACTOME_CLEC7A_DECTIN_1_INDUCES_NFAT_ACTIVATION	ITPR1 ITPR2	1.34e-03	11	71	2	M27466
Pathway	KEGG_MEDICUS_ENV_FACTOR_NNK_NNN_TO_PI3K_SIGNALING_PATHWAY_N01339	PIK3CA MTOR	1.34e-03	11	71	2	M47791
Pathway	KEGG_MEDICUS_REFERENCE_IGF2_IGF1R_PI3K_SIGNALING_PATHWAY	PIK3CA MTOR	1.34e-03	11	71	2	M47484
Pathway	KEGG_MEDICUS_REFERENCE_EREG_EGFR_PI3K_SIGNALING_PATHWAY	PIK3CA MTOR	1.34e-03	11	71	2	M47499
Pathway	KEGG_MEDICUS_REFERENCE_AREG_EGFR_PI3K_SIGNALING_PATHWAY	PIK3CA MTOR	1.34e-03	11	71	2	M47501
Pathway	KEGG_MEDICUS_REFERENCE_TSC1_2_MTORC1_SIGNALING_PATHWAY	MTOR TSC2	1.34e-03	11	71	2	M47915
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	USP36 VWA8 NBEAL2 ARHGAP26 KIF21A LAMA5 CDK5RAP2 CRTC1 SIK3 AGAP7P AGAP4 CNOT1 AGAP6 SMG6	1.98e-10	529	95	14	14621295
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	MDN1 LZTS1 MTOR NTRK2 PPFIA1 KIF21A CDK5RAP2 TSC2 SIK3 ZBTB1 CNOT1 TRIM3 KLC1 EPHA4 SMG6	5.43e-08	963	95	15	28671696
Pubmed	PI3K-p110-alpha-subtype signalling mediates survival, proliferation and neurogenesis of cortical progenitor cells via activation of mTORC2.	PIK3CA MTOR CRTC1	7.88e-08	4	95	3	24645666
Pubmed	The TRIM9/TRIM67 neuronal interactome reveals novel activators of morphogenesis.	EVL SH3RF1 PIK3CA TNRC6C AGAP7P AGAP4 AGAP6 SMG6	1.60e-07	218	95	8	33378226
Pubmed	TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile.	AMPD1 MDN1 IPO7 TRAPPC12 LZTS1 ARHGAP26 POT1 PARD6G CDK5RAP2 SIK3 CNOT1 KDM6A	1.79e-07	638	95	12	31182584
Pubmed	IκB kinase complex (IKK) triggers detachment-induced autophagy in mammary epithelial cells independently of the PI3K-AKT-MTORC1 pathway.	PIK3CA MTOR TSC2	6.86e-07	7	95	3	23778976
Pubmed	Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.	PIK3CA MTOR TSC2	1.09e-06	8	95	3	20622004
Pubmed	GGAPs, a new family of bifunctional GTP-binding and GTPase-activating proteins.	AGAP7P AGAP4 AGAP6	1.64e-06	9	95	3	12640130
Pubmed	AGAP1/AP-3-dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release.	AGAP7P AGAP4 AGAP6	2.34e-06	10	95	3	20664521
Pubmed	AGAP1, a novel binding partner of nitric oxide-sensitive guanylyl cyclase.	AGAP7P AGAP4 AGAP6	3.21e-06	11	95	3	15381706
Pubmed	Protein interactome reveals converging molecular pathways among autism disorders.	EVL MSANTD3 UXS1 DACH2 LAMA5 TSC2 AGAP7P TRIM3 KLC1 PHC2	3.21e-06	560	95	10	21653829
Pubmed	Single nucleotide polymorphisms of matrix metalloproteinase 9 (MMP9) and tumor protein 73 (TP73) interact with Epstein-Barr virus in chronic lymphocytic leukemia: results from the European case-control study EpiLymph.	PHAF1 TRAF6 PIK3CA MTOR TICAM1 POT1 TSC2	3.50e-06	231	95	7	21048031
Pubmed	The Endosome Localized Arf-GAP AGAP1 Modulates Dendritic Spine Morphology Downstream of the Neurodevelopmental Disorder Factor Dysbindin.	AGAP7P AGAP4 AGAP6	5.54e-06	13	95	3	27713690
Pubmed	Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms.	MDN1 IPO7 VWA8 CEBPZ MTOR TMOD1 CDK5RAP2 TNRC6C SIK3 TRIM3 NUP54	6.92e-06	754	95	11	33060197
Pubmed	GTP-binding protein-like domain of AGAP1 is protein binding site that allosterically regulates ArfGAP protein catalytic activity.	AGAP7P AGAP4 AGAP6	7.03e-06	14	95	3	22453919
Pubmed	Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells.	PIK3CA MTOR	7.38e-06	2	95	2	27189717
Pubmed	Loss of TSC2 confers resistance to ceramide and nutrient deprivation.	MTOR TSC2	7.38e-06	2	95	2	23604129
Pubmed	mTORC1 silencing during intestinal epithelial Caco-2 cell differentiation is mediated by the activation of the AMPK/TSC2 pathway.	CRTC1 TSC2	7.38e-06	2	95	2	33561653
Pubmed	Immunolocalization of type 2 inositol 1,4,5-trisphosphate receptors in cardiac myocytes from newborn mice.	ITPR1 ITPR2	7.38e-06	2	95	2	15201137
Pubmed	Inhibition of phosphoinositide 3-kinase enhances TRIF-dependent NF-kappa B activation and IFN-beta synthesis downstream of Toll-like receptor 3 and 4.	PIK3CA TICAM1	7.38e-06	2	95	2	15940673
Pubmed	Helicobacter pylori promotes eukaryotic protein translation by activating phosphatidylinositol 3 kinase/mTOR.	PIK3CA MTOR	7.38e-06	2	95	2	25194338
Pubmed	Sulphide signalling potentiates apoptosis through the up-regulation of IP3 receptor types 1 and 2.	ITPR1 ITPR2	7.38e-06	2	95	2	23582047
Pubmed	mTORC2 is required for proliferation and survival of TSC2-null cells.	MTOR TSC2	7.38e-06	2	95	2	21482669
Pubmed	Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.	PIK3CA MTOR	7.38e-06	2	95	2	21372221
Pubmed	PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.	PIK3CA MTOR	7.38e-06	2	95	2	20479250
Pubmed	[PI3K and mTOR pathway and molecular targeted agents].	PIK3CA MTOR	7.38e-06	2	95	2	26281684
Pubmed	Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress.	MTOR TSC2	7.38e-06	2	95	2	23699409
Pubmed	Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinoma.	PIK3CA MTOR	7.38e-06	2	95	2	23867512
Pubmed	TSC2 regulates VEGF through mTOR-dependent and -independent pathways.	MTOR TSC2	7.38e-06	2	95	2	12957289
Pubmed	Tsc2 is a molecular checkpoint controlling osteoblast development and glucose homeostasis.	MTOR TSC2	7.38e-06	2	95	2	24591652
Pubmed	Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression.	PIK3CA MTOR	7.38e-06	2	95	2	24263107
Pubmed	Type 1 and 2 IP3 receptors respond differently to catecholamines and stress.	ITPR1 ITPR2	7.38e-06	2	95	2	19120126
Pubmed	Structural insights of a PI3K/mTOR dual inhibitor with the morpholino-triazine scaffold.	PIK3CA MTOR	7.38e-06	2	95	2	26956874
Pubmed	Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-dependent manner.	CRTC1 TSC2	7.38e-06	2	95	2	18587048
Pubmed	mTOR-related synaptic pathology causes autism spectrum disorder-associated functional hyperconnectivity.	MTOR TSC2	7.38e-06	2	95	2	34667149
Pubmed	Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.	MTOR DYRK2	7.38e-06	2	95	2	27746162
Pubmed	Development of hypomelanotic macules is associated with constitutive activated mTORC1 in tuberous sclerosis complex.	MTOR TSC2	7.38e-06	2	95	2	28336152
Pubmed	KIF21A-mediated axonal transport and selective endocytosis underlie the polarized targeting of NCKX2.	SLC24A2 KIF21A	7.38e-06	2	95	2	22442075
Pubmed	Decreased rates of cerebral protein synthesis measured in vivo in a mouse model of Tuberous Sclerosis Complex: unexpected consequences of reduced tuberin.	MTOR TSC2	7.38e-06	2	95	2	29364507
Pubmed	Ehrlichia Activation of Wnt-PI3K-mTOR Signaling Inhibits Autolysosome Generation and Autophagic Destruction by the Mononuclear Phagocyte.	PIK3CA MTOR	7.38e-06	2	95	2	28993455
Pubmed	Signals mediating skeletal muscle remodeling by resistance exercise: PI3-kinase independent activation of mTORC1.	PIK3CA MTOR	7.38e-06	2	95	2	21071597
Pubmed	Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer.	PIK3CA MTOR	7.38e-06	2	95	2	25497009
Pubmed	Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway.	MTOR TSC2	7.38e-06	2	95	2	22287548
Pubmed	Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.	PIK3CA MTOR	7.38e-06	2	95	2	27507059
Pubmed	Identification and characterisation of novel mammalian homologues of Drosophila polyhomeoticpermits new insights into relationships between members of the polyhomeotic family.	PHC3 PHC2	7.38e-06	2	95	2	12384788
Pubmed	Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.	PIK3CA MTOR	7.38e-06	2	95	2	20857497
Pubmed	Tuberous Sclerosis Complex Protein 2-Independent Activation of mTORC1 by Human Cytomegalovirus pUL38.	MTOR TSC2	7.38e-06	2	95	2	25972538
Pubmed	An antidepressant behaviour in mice carrying a gene-specific InsP3R1, InsP3R2 and InsP3R3 protein knockdown.	ITPR1 ITPR2	7.38e-06	2	95	2	18708078
Pubmed	In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.	PIK3CA MTOR	7.38e-06	2	95	2	27765909
Pubmed	NFAT5 Deficiency Alleviates Formalin-Induced Inflammatory Pain Through mTOR.	MTOR NFAT5	7.38e-06	2	95	2	33806698
Pubmed	A role of the mammalian target of rapamycin (mTOR) in glutamate-induced down-regulation of tuberous sclerosis complex proteins 2 (TSC2).	MTOR TSC2	7.38e-06	2	95	2	22492229
Pubmed	The tumor-suppressor gene LZTS1 suppresses colorectal cancer proliferation through inhibition of the AKT-mTOR signaling pathway.	LZTS1 MTOR	7.38e-06	2	95	2	25667121
Pubmed	Ablation of TSC2 enhances insulin secretion by increasing the number of mitochondria through activation of mTORC1.	MTOR TSC2	7.38e-06	2	95	2	21886784
Pubmed	mTOR Hyperactivation by Ablation of Tuberous Sclerosis Complex 2 in the Mouse Heart Induces Cardiac Dysfunction with the Increased Number of Small Mitochondria Mediated through the Down-Regulation of Autophagy.	MTOR TSC2	7.38e-06	2	95	2	27023784
Pubmed	TRAF6 interacts with and ubiquitinates PIK3CA to enhance PI3K activation.	TRAF6 PIK3CA	7.38e-06	2	95	2	29729098
Pubmed	The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.	PIK3CA MTOR	7.38e-06	2	95	2	25491778
Pubmed	GW182 proteins cause PABP dissociation from silenced miRNA targets in the absence of deadenylation.	TNRC6C CNOT1	7.38e-06	2	95	2	23463101
Pubmed	Pancreatic β-cell failure mediated by mTORC1 hyperactivity and autophagic impairment.	MTOR TSC2	7.38e-06	2	95	2	24740570
Pubmed	A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape.	PPAN MDN1 IPO7 BMP2K VWA8 CEBPZ MTOR TMOD1 TSC2 COPS3 SLC25A28 CNOT1 GFM2 ITPR1 ITPR2	8.22e-06	1440	95	15	30833792
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	MDN1 SH3RF1 VWA8 TRAPPC12 MTOR NBEAL2 ARHGAP26 LAMA5 TSC2 TNRC6C PHC2 SMG6 ITPR2	9.81e-06	1105	95	13	35748872
Pubmed	CTDP1 regulates breast cancer survival and DNA repair through BRCT-specific interactions with FANCI.	MDN1 PPFIA1 HELZ TSC2 ITPR1	1.02e-05	104	95	5	31240132
Pubmed	The RNA-mediated estrogen receptor α interactome of hormone-dependent human breast cancer cell nuclei.	USP36 BCL9L PHC3 UXS1 PPAN SUPT20H MDN1 BMP2K CEBPZ PPFIA1 LAMA5 HELZ CRTC1 PHC2 SMG6	1.30e-05	1497	95	15	31527615
Pubmed	Suppression subtractive hybridization and expression profiling identifies a unique set of genes overexpressed in non-small-cell lung cancer.	MSANTD3 SIK3 ZBTB1	1.85e-05	19	95	3	15334068
Pubmed	Tuberous sclerosis complex proteins 1 and 2 control serum-dependent translation in a TOP-dependent and -independent manner.	MTOR TSC2	2.21e-05	3	95	2	17562867
Pubmed	Evidence that type I, II, and III inositol 1,4,5-trisphosphate receptors can occur as integral plasma membrane proteins.	ITPR1 ITPR2	2.21e-05	3	95	2	10874040
Pubmed	[Study of gambogenic acid-induced apoptosis of melanoma B16 cells through PI3K/Akt/mTOR signaling pathways].	PIK3CA MTOR	2.21e-05	3	95	2	25095381
Pubmed	Targeting the PI3K/AKT/mTOR signaling pathway in medulloblastoma.	PIK3CA MTOR	2.21e-05	3	95	2	25601471
Pubmed	Abnormal distribution of inositol 1,4,5-trisphosphate receptors in human muscle can be related to altered calcium signals and gene expression in Duchenne dystrophy-derived cells.	ITPR1 ITPR2	2.21e-05	3	95	2	20395455
Pubmed	Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.	MTOR TSC2	2.21e-05	3	95	2	15624760
Pubmed	Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance.	PIK3CA MTOR	2.21e-05	3	95	2	25215588
Pubmed	Inositol 1,4,5-trisphosphate receptors are autoantibody target antigens in patients with Sjögren's syndrome and other systemic rheumatic diseases.	ITPR1 ITPR2	2.21e-05	3	95	2	17437169
Pubmed	PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival.	RASA1 PIK3CA	2.21e-05	3	95	2	19012001
Pubmed	Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.	PIK3CA MTOR	2.21e-05	3	95	2	25108739
Pubmed	Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer.	PIK3CA MTOR	2.21e-05	3	95	2	27626684
Pubmed	PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).	PIK3CA MTOR	2.21e-05	3	95	2	25757539
Pubmed	Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain.	MTOR TSC2	2.21e-05	3	95	2	17018601
Pubmed	mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability.	MTOR TSC2	2.21e-05	3	95	2	29056426
Pubmed	Decreased olfactory mucus secretion and nasal abnormality in mice lacking type 2 and type 3 IP3 receptors.	ITPR1 ITPR2	2.21e-05	3	95	2	18547250
Pubmed	Uncoupling of ER/Mitochondrial Oxidative Stress in mTORC1 Hyperactivation-Associated Skin Hypopigmentation.	CRTC1 TSC2	2.21e-05	3	95	2	29080681
Pubmed	Inositol 1,4,5-trisphosphate receptor gene variants are related to the risk of breast cancer in a Chinese population.	ITPR1 ITPR2	2.21e-05	3	95	2	36350267
Pubmed	Inositol 1,4,5-trisphosphate receptors are essential for fetal-maternal connection and embryo viability.	ITPR1 ITPR2	2.21e-05	3	95	2	32320395
Pubmed	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.	MTOR TSC2	2.21e-05	3	95	2	26831717
Pubmed	The versatility and universality of calcium signalling.	ITPR1 ITPR2	2.21e-05	3	95	2	11413485
Pubmed	Down-regulation of JAK1 by RNA interference inhibits growth of the lung cancer cell line A549 and interferes with the PI3K/mTOR pathway.	PIK3CA MTOR	2.21e-05	3	95	2	21861134
Pubmed	Using concatenated subunits to investigate the functional consequences of heterotetrameric inositol 1,4,5-trisphosphate receptors.	ITPR1 ITPR2	2.21e-05	3	95	2	26009177
Pubmed	Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study.	MTOR TSC2	2.21e-05	3	95	2	32091432
Pubmed	Nerve growth factor regulates the expression of vascular endothelial growth factor in human HaCaT keratinocytes via PI3K/mTOR pathway.	PIK3CA MTOR	2.21e-05	3	95	2	24615084
Pubmed	Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.	MTOR TSC2	2.21e-05	3	95	2	35099634
Pubmed	Receptor-activated single channels in intact human platelets.	ITPR1 ITPR2	2.21e-05	3	95	2	1693919
Pubmed	Functional inositol 1,4,5-trisphosphate receptors assembled from concatenated homo- and heteromeric subunits.	ITPR1 ITPR2	2.21e-05	3	95	2	23955339
Pubmed	Type 3 Inositol 1,4,5-Trisphosphate Receptor is a Crucial Regulator of Calcium Dynamics Mediated by Endoplasmic Reticulum in HEK Cells.	ITPR1 ITPR2	2.21e-05	3	95	2	31979185
Pubmed	Epigenetic regulation of autophagy by the methyltransferase EZH2 through an MTOR-dependent pathway.	MTOR TSC2	2.21e-05	3	95	2	26735435
Pubmed	The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism.	PIK3CA MTOR	2.21e-05	3	95	2	23626817
Pubmed	Tsg101 regulates PI(4,5)P2/Ca(2+) signaling for HIV-1 Gag assembly.	ITPR1 ITPR2	2.21e-05	3	95	2	24904548
Pubmed	Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.	PIK3CA MTOR	2.21e-05	3	95	2	25122428
Pubmed	Platelet-derived growth factor/vascular endothelial growth factor receptor inactivation by sunitinib results in Tsc1/Tsc2-dependent inhibition of TORC1.	MTOR TSC2	2.21e-05	3	95	2	23878397
Pubmed	Nutrient signaling in protein homeostasis: an increase in quantity at the expense of quality.	MTOR TSC2	2.21e-05	3	95	2	23592839
Pubmed	Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 and multisite phosphorylation.	MTOR CRTC1	2.21e-05	3	95	2	19864431
Pubmed	XLID CUL4B mutants are defective in promoting TSC2 degradation and positively regulating mTOR signaling in neocortical neurons.	MTOR TSC2	2.21e-05	3	95	2	23348097
Pubmed	Targeting PI3 kinase/AKT/mTOR signaling in cancer.	PIK3CA MTOR	2.21e-05	3	95	2	22471665
GeneFamily	Inositol 1,4,5-triphosphate receptors\|Protein phosphatase 1 regulatory subunits	ITPR1 ITPR2	3.93e-05	3	66	2	297
GeneFamily	ArfGAPs	AGAP7P AGAP4 AGAP6	2.34e-04	33	66	3	395
GeneFamily	Sterile alpha motif domain containing	PHC3 PPFIA1 PHC2 EPHA4	3.00e-04	88	66	4	760
GeneFamily	Tetratricopeptide repeat domain containing\|Bardet-Biedl syndrome associated\|BBSome	TRAPPC12 CFAP70 KDM6A KLC1	8.26e-04	115	66	4	769
GeneFamily	X-linked mental retardation\|Rho GTPase activating proteins\|BAR-PH domain containing	AGAP4 AGAP6	1.72e-03	17	66	2	1291
GeneFamily	CD molecules\|Integrin alpha subunits	ITGA11 ITGAL	1.93e-03	18	66	2	1160
GeneFamily	Ataxins\|Trinucleotide repeat containing	CELF3 TNRC6C	3.73e-03	25	66	2	775
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	ADORA2B SUPT20H MDN1 IPO7 RASA1 BMP2K PPFIA1 HELZ SIK3 VCL KLC1 EPHA4 ITPR1	1.45e-05	856	96	13	M4500
Coexpression	BUSSLINGER_GASTRIC_IMMUNE_CELLS	PTBP3 EVL PHC3 MCMBP RASA1 NBEAL2 HELZ TNRC6C SIK3 ITGAL NFAT5 ZBTB1 CNOT1 KLC1 ITPR1 DYRK2 ITPR2	2.71e-05	1492	96	17	M40023
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HGABA	PTBP3 MDN1 SEMA6D SLC24A2 KIF21A CELF3 LAMA5 TSC2 TMCO3 TNRC6C SIK3 CAMTA1 KLC1 DYRK2	4.96e-05	1106	96	14	M39071
Coexpression	IKEDA_MIR30_TARGETS_UP	PTBP3 SEMA6D RASA1 PPFIA1 NFAT5	6.90e-05	116	96	5	M2379
Coexpression	IKEDA_MIR30_TARGETS_UP	PTBP3 SEMA6D RASA1 PPFIA1 NFAT5	7.19e-05	117	96	5	MM931
Coexpression	GSE39820_CTRL_VS_TGFBETA1_IL6_IL23A_CD4_TCELL_UP	PHC3 IKZF2 AGR3 SIK3 KDM6A ITPR1	9.34e-05	199	96	6	M5607
Coexpression	GSE369_SOCS3_KO_VS_WT_LIVER_DN	TRAF6 SUPT20H CDK5RAP2 SIK3 CAMTA1 ZBTB1	9.60e-05	200	96	6	M5963
Coexpression	GSE19401_UNSTIM_VS_RETINOIC_ACID_STIM_FOLLICULAR_DC_UP	VWA8 NBEAL2 ITGAL PGD IFNA14 ITPR1	9.60e-05	200	96	6	M7661
Coexpression	GSE10240_CTRL_VS_IL22_STIM_PRIMARY_BRONCHIAL_EPITHELIAL_CELLS_UP	BMP2K NBEAL2 KIF21A CRTC1 ITGAL ITPR1	9.60e-05	200	96	6	M302
Coexpression	GSE360_T_GONDII_VS_B_MALAYI_HIGH_DOSE_DC_DN	AMPD1 TRAPPC12 ARHGAP26 ZBTB1 VCL ITPR2	9.60e-05	200	96	6	M5216
Coexpression	GSE20715_0H_VS_6H_OZONE_LUNG_DN	PDXDC1 PHAF1 MSANTD3 PDK4 LAMA5 AGR3	9.60e-05	200	96	6	M4365
Coexpression	GSE21670_TGFB_VS_TGFB_AND_IL6_TREATED_STAT3_KO_CD4_TCELL_UP	PPAN CEBPZ PIK3CA PARD6G SLC25A28 DYRK2	9.60e-05	200	96	6	M7446
CoexpressionAtlas	dev gonad_e13.5_F_SupCellPrec_Sry_k-means-cluster#2_top-relative-expression-ranked_500	PHAF1 SEMA6D PDK4 ARHGAP26 NFAT5 KDM6A ITPR2	7.44e-06	161	94	7	gudmap_dev gonad_e13.5_F_SupCellPrec_Sry_k2_500
CoexpressionAtlas	DevelopingKidney_e15.5_anlage of loop of Henle_emap-31283_k-means-cluster#3_top-relative-expression-ranked_1000	IKZF2 SH3RF1 VWA8 ABCA13 PIK3CA POT1 DACH1 NFAT5 EPHA4	4.68e-05	379	94	9	gudmap_developingKidney_e15.5_1000_k3
ToppCell	367C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_3\|CD8+_Cytotoxic_T-cell / Donor, Lineage, Cell class and subclass (all cells)	VWA8 TRAPPC12 MTOR NTRK2 ITGAL ZNF114	1.51e-06	164	96	6	d2218d50e0e2d19f919dcb460b3840687c082810
ToppCell	10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8\|GI_small-bowel / Manually curated celltypes from each tissue	ARHGAP26 SIK3 NFAT5 KDM6A ITPR1 SMG6	3.33e-06	188	96	6	ab9b725d6e0cdab8e9ddda6dee09e14730e9a578
ToppCell	COVID_non-vent-Lymphocytic-T_cell-CD8+_Memory_T_cell\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	BCL9L EVL IKZF2 KIF21A ITGAL ZBTB1	4.36e-06	197	96	6	836061acd7f0d5de89b16f52ec679bdf09eac9db
ToppCell	PBMC-Mild-Lymphocyte-T/NK-Other_T-gd_T-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	BCL9L EVL IKZF2 KIF21A ITGAL ZBTB1	4.49e-06	198	96	6	a1b310274aa9b3d2aa1fe9488d67422bf4ac81d2
ToppCell	PBMC-Mild-Lymphocyte-T/NK-Other_T-gd_T\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	BCL9L EVL IKZF2 KIF21A ITGAL ZBTB1	4.49e-06	198	96	6	76aff381403bc5a8a9cc73eb1e5dbdc0bac7de6c
ToppCell	PBMC-Mild-Lymphocyte-T/NK-Other_T-gd_T\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	BCL9L EVL IKZF2 KIF21A ITGAL ZBTB1	4.49e-06	198	96	6	a781fd35a7cda8b7760c2e3ddccaac7aac26c979
ToppCell	PBMC-Mild-Lymphocyte-T/NK-Other_T-gd_T-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	BCL9L EVL IKZF2 KIF21A ITGAL ZBTB1	4.49e-06	198	96	6	df399674345c45738d765a8354ea8d1484572c34
ToppCell	COVID-19_Mild-Lymphoid_T/NK-gd_T\|COVID-19_Mild / Disease group, lineage and cell class	BCL9L EVL IKZF2 KIF21A ITGAL ZBTB1	4.49e-06	198	96	6	6aea5d00c417708f05b6d2dfe5a962d80864f8eb
ToppCell	COVID-19-COVID-19_Mild-Lymphocyte-T/NK-gd_T\|COVID-19_Mild / Disease, condition lineage and cell class	BCL9L EVL IKZF2 KIF21A ITGAL ZBTB1	4.76e-06	200	96	6	6560753d3df2f87860b52052d4881aa45410f666
ToppCell	mild-gd_T\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	BCL9L IKZF2 CEBPZ KIF21A ITGAL ZBTB1	4.76e-06	200	96	6	109f673a4967ffa52270a0b4f818b3461288db44
ToppCell	Epithelial-Epithelial-B_(AT1-AT2-progenitors)\|Epithelial / shred on cell class and cell subclass (v4)	MDN1 RASA1 LZTS1 OTOP2 ITPR1	2.09e-05	154	96	5	770712806e26f73456fb77a81aa4ef8ec78a21ea
ToppCell	droplet-Spleen-nan-21m-Myeloid-granulocyte\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MSANTD3 ABCA13 DACH1 PGD VCL	3.09e-05	167	96	5	cfcd72292c733cdb18c92fdb61b68f6806d22c8c
ToppCell	droplet-Spleen-SPLEEN-30m-Myeloid-granulocyte\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MSANTD3 ABCA13 DACH1 PGD VCL	3.18e-05	168	96	5	c0ff30e2c47005514131a0866cf10a1c228128fc
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	COLEC12 ITGA11 DACH2 DACH1 SLC2A12	4.41e-05	180	96	5	280ff5c8f292be1b88120db5ff1788b750644856
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	COLEC12 ITGA11 DACH2 DACH1 SLC2A12	4.41e-05	180	96	5	fdbd7c22044d9328a1e06e2f9a4451529d1df767
ToppCell	renal_papilla_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	PTBP3 IKZF2 DACH2 PDK4 NFAT5	4.41e-05	180	96	5	49829e833fe6d2431cfd2e8f378c2aaa3b2b46a4
ToppCell	facs-Marrow-T-cells-3m-Myeloid\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADORA2B BMP2K LAMA5 ITGAL ITPR1	4.53e-05	181	96	5	7286700396676fdc41d9723979b8b408177aceb9
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	SEMA6D NTRK2 CFAP70 ITPR1 ITPR2	4.77e-05	183	96	5	31ab55d5f3639f5964541d5eae23044dbda3356e
ToppCell	COVID-19_Mild-gd_T\|COVID-19_Mild / Disease condition and Cell class	IKZF2 ARHGAP26 ITGAL ZBTB1 VCL	4.77e-05	183	96	5	f593a89b0aa8fffdfa403769916facfd30358521
ToppCell	COVID-19-kidney-Podocyte\|kidney / Disease (COVID-19 only), tissue and cell type	DACH2 DACH1 TMOD1 PARD6G SLC2A12	4.77e-05	183	96	5	fb5e2a31b560126e1c04a386c24c365901c60ad7
ToppCell	human_hepatoblastoma-Hepatic_Stellate_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	ITGA11 SH3RF1 SEMA6D LZTS1 ITPR1	5.16e-05	186	96	5	cb1fc4b9140666b43415e21c9b434dc9b144e9d0
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Cortical_Thick_Ascending_Limb_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	SEMA6D NTRK2 CFAP70 ITPR1 ITPR2	5.29e-05	187	96	5	b93cf4dfe8ffb89348ee7bccc9f284189f7240a2
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Cortical_Thick_Ascending_Limb_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	SEMA6D NTRK2 CFAP70 EPHA4 ITPR1	5.43e-05	188	96	5	2ee64bc73a2251fd9f374be759b442cf4ed0d19e
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ITGA11 DACH2 DACH1 PHC2 ITPR1	5.56e-05	189	96	5	c734e5693808a0333139e87bd5be2597a9252afe
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ITGA11 DACH2 DACH1 PHC2 ITPR1	5.70e-05	190	96	5	2e592323085ba9c019d678ac2a784462ab470ed9
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ITGA11 DACH2 DACH1 PHC2 ITPR1	5.70e-05	190	96	5	445952b70abffadb6ccc1ed4bbf61a88b06b73b3
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ITGA11 DACH2 DACH1 PHC2 ITPR1	5.85e-05	191	96	5	c54c420a94dc749ebc67fc64c5614663f4b9798d
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	COLEC12 ITGA11 DACH2 DACH1 SLC2A12	5.85e-05	191	96	5	1caf726bd07fdca389e678fc16304a6ef1790423
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ITGA11 DACH2 DACH1 PHC2 ITPR1	5.85e-05	191	96	5	cb0aee740b08f7d5fdd2717ecf7429043b277ae7
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	COLEC12 ITGA11 DACH2 DACH1 SLC2A12	5.85e-05	191	96	5	3d60c46bced2984c27a1fcf2910bc38b31fb0148
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Mesenchymal\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	COLEC12 ITGA11 DACH2 DACH1 SLC2A12	5.99e-05	192	96	5	4022f208eb5db760abd0aac782a25e8ab63efc64
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	COLEC12 ITGA11 DACH2 DACH1 SLC2A12	5.99e-05	192	96	5	9333aba0d04203ccccad78d82bf6359922f810a7
ToppCell	Fibroblasts-CD55+_Fibroblasts\|World / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues	KIAA0408 COLEC12 SEMA6D TMOD1 SLC2A12	6.14e-05	193	96	5	8f4bf9a2fbedae35432dad96730b00c70185874c
ToppCell	nucseq\|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	RASA1 ARHGAP26 SIK3 NFAT5 KDM6A	6.14e-05	193	96	5	779276e775cb2492e8dd36436295a536084a6415
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c06-TNF\|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)	EVL IKZF2 KIF21A TNRC6C ITGAL	6.30e-05	194	96	5	0fdf4d7d42d8f1f47eade2fb89ff35b188b9b51f
ToppCell	COVID-19-Myeloid-Monocyte-derived_macrophages\|COVID-19 / group, cell type (main and fine annotations)	COLEC12 BMP2K PDK4 ARHGAP26 ITPR2	6.45e-05	195	96	5	c172c5599379c29123340621a36bfb1fc90c2115
ToppCell	COVID-19_Severe-Neu_2\|World / 5 Neutrophil clusters in COVID-19 patients	PDXDC1 ABCA13 DACH1 PGD VCL	6.61e-05	196	96	5	16359a56297f0558fc93fa52563cce0c53def167
ToppCell	Healthy/Control-CD8+_Tem\|World / Disease group and Cell class	USP36 BCL9L EVL KIF21A PARD6G	6.61e-05	196	96	5	a6dc92476156a695e15373ea57dc04e30014ac55
ToppCell	B_cells-Memory_B_cells\|B_cells / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues	EVL BMP2K EPHA4 ITPR1 DYRK2	6.77e-05	197	96	5	cdd1dbdaf257b0864c6dc8c1cbed6e9b68e114b7
ToppCell	COVID-19_Severe-Neu_2\|COVID-19_Severe / 5 Neutrophil clusters in COVID-19 patients	PDXDC1 ABCA13 DACH1 PGD VCL	6.77e-05	197	96	5	945f19475905cdedf232315eea1076ca0b753b67
ToppCell	mild_COVID-19-CD8+_Tem\|mild_COVID-19 / disease group, cell group and cell class (v2)	USP36 BCL9L EVL KIF21A PARD6G	6.93e-05	198	96	5	12847340c36a6791d8bdcb81e731e2fdeec46326
ToppCell	Tracheal-NucSeq\|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations	VWA8 ARHGAP26 SIK3 KDM6A ITPR2	7.10e-05	199	96	5	94b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCell	severe-gd_T\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	EVL IKZF2 KIF21A ITGAL ZBTB1	7.10e-05	199	96	5	e5a17a9f8f3be05d6abe1116607d17633df3c7ef
ToppCell	LPS_anti-TNF-Mesenchymal_myocytic-Pericyte-Pericyte_2\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	SEMA6D LZTS1 TMOD1 VCL DYRK2	7.27e-05	200	96	5	786f1ae53e60b5ffbf4bfd393d10b802478148b3
ToppCell	LPS_IL1RA-Mesenchymal_myocytic\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	KIAA0408 LZTS1 TMOD1 VCL ITPR1	7.27e-05	200	96	5	77631c471cc5d453a749784f838cfa6408caf09b
ToppCell	Control_saline-Mesenchymal_myocytic-Pericyte-Pericyte_2\|Control_saline / Treatment groups by lineage, cell group, cell type	SEMA6D LZTS1 TMOD1 VCL DYRK2	7.27e-05	200	96	5	bc8949eb34482aca166c4602ff6ab876cb4c2c3c
ToppCell	facs-Lung-Endomucin-24m-Lymphocytic-Natural_Killer\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RASA1 VWA8 CEBPZ MTOR	1.05e-04	113	96	4	357bc20edc5bc14eab8262d52260ed1686e9dc54
ToppCell	facs-Lung-Endomucin-24m-Lymphocytic-NK_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RASA1 VWA8 CEBPZ MTOR	1.05e-04	113	96	4	91e73e3b93be242fef0f14eddd8085a1f1c730ef
Drug	Kaempferol [520-18-3]; Down 200; 14uM; HL60; HT_HG-U133A	VWA8 NBEAL2 PPFIA1 DACH1 TMOD1 TMCO3 ITGAL NPFFR1	1.55e-06	194	95	8	6157_DN
Drug	everolimus	EVL PIK3CA MTOR CRTC1 TSC2 NFAT5 ITPR1	1.66e-06	136	95	7	CID006442177
Drug	Isocorydine (+) [475-67-2]; Down 200; 11.8uM; PC3; HT_HG-U133A	USP36 PTBP3 SUPT20H ARHGAP26 HERC3 NFAT5 ZBTB1 DYRK2	1.95e-06	200	95	8	4505_DN
Drug	troglitazone; Down 200; 10uM; MCF7; HT_HG-U133A	PTBP3 SUPT20H BMP2K DACH1 TSC2 SLC25A28 NPFFR1	1.78e-05	195	95	7	1657_DN
Drug	Piromidic acid [19562-30-2]; Down 200; 13.8uM; MCF7; HT_HG-U133A	PHC3 BMP2K TICAM1 CRTC1 NFAT5 ZBTB1 TRIM3	1.78e-05	195	95	7	4398_DN
Drug	Solasodine [126-17-0]; Down 200; 9.6uM; MCF7; HT_HG-U133A	AMPD1 TRAF6 ARHGAP26 CRTC1 EIF2AK1 KDM6A ITPR2	1.83e-05	196	95	7	3830_DN
Drug	Piperacillin sodium salt [59703-84-3]; Down 200; 7.4uM; PC3; HT_HG-U133A	PDK4 HERC3 NPFFR1 EPHA4 ITPR1 SMG6 ITPR2	1.90e-05	197	95	7	3763_DN
Drug	0316684-0000 [391209-55-5]; Up 200; 10uM; MCF7; HT_HG-U133A	AMPD1 SUPT20H BMP2K TMOD1 NFAT5 NPFFR1 TRIM3	1.90e-05	197	95	7	7093_UP
Drug	N6,2-O-dibutyryladenosine 3,5-cyclic monophosphate sodium salt; Up 200; 2uM; MCF7; HT_HG-U133A_EA	USP36 PHC3 NTRK2 LAMA5 CDK5RAP2 SIK3 EIF2AK1	1.90e-05	197	95	7	959_UP
Drug	Dicumarol [66-76-2]; Down 200; 11.8uM; MCF7; HT_HG-U133A	BMP2K NBEAL2 CDK5RAP2 SIK3 NFAT5 TRIM3 EPHA4	1.96e-05	198	95	7	3423_DN
Drug	Aminophylline [317-34-0]; Up 200; 9.6uM; MCF7; HT_HG-U133A	BMP2K LZTS1 NBEAL2 NTRK2 TICAM1 ITPR1 SMG6	2.02e-05	199	95	7	5395_UP
Drug	Trolox [53188-07-1]; Down 200; 16uM; MCF7; HT_HG-U133A	USP36 MCMBP MTOR TMOD1 KDM6A TRIM3 ITPR1	2.02e-05	199	95	7	2883_DN
Drug	Bromperidol [10457-90-6]; Down 200; 9.6uM; MCF7; HT_HG-U133A	PTBP3 BMP2K NBEAL2 EIF2AK1 KDM6A DYRK2 ITPR2	2.02e-05	199	95	7	2872_DN
Drug	Cefmetazole sodium salt [56796-39-5]; Down 200; 8.2uM; MCF7; HT_HG-U133A	PHC3 SEMA6D PDK4 DACH1 TMOD1 HERC3 NPFFR1	2.02e-05	199	95	7	6086_DN
Drug	Tungsten Compounds	COLEC12 DACH1 LAMA5 TMOD1 EPHA4	6.57e-05	101	95	5	ctd:D017973
Drug	A-443654	PIK3CA MTOR TSC2	7.62e-05	20	95	3	CID010172943
Drug	cis isomer	UGT1A4 EVL UGT1A5 DACH1	1.02e-04	58	95	4	CID006474725
Drug	a-X-d	MTOR LAMA5 VCL	1.02e-04	22	95	3	CID011987862
Drug	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	PIK3CA MTOR	1.03e-04	4	95	2	ctd:C499693
Drug	Salbutamol [18559-94-9]; Up 200; 16.8uM; PC3; HT_HG-U133A	PTBP3 PHC3 ITGAL TRIM3 ITPR1 ITPR2	1.34e-04	187	95	6	3677_UP
Drug	Econazole nitrate [24169-02-6]; Up 200; 9uM; MCF7; HT_HG-U133A	TRAF6 BMP2K ARHGAP26 TICAM1 ZBTB1 KDM6A	1.38e-04	188	95	6	7427_UP
Drug	wartmannin	ADORA2B COLEC12 TRAF6 RASA1 PIK3CA MTOR NTRK2 LAMA5 CDK5RAP2 TSC2 NFAT5 SLC2A12	1.40e-04	811	95	12	CID000005691
Drug	Sulfamethazine sodium salt [1981-58-4]; Down 200; 13.4uM; PC3; HT_HG-U133A	USP36 PTBP3 HERC3 NFAT5 NPFFR1 KDM6A	1.47e-04	190	95	6	4322_DN
Drug	5-hydroxymethylfurfural	PPAN CEBPZ PGD VCL	1.58e-04	65	95	4	CID000237332
Drug	2-propylpentanoic acid; Up 200; 50uM; MCF7; HT_HG-U133A_EA	SUPT20H VWA8 NFAT5 KDM6A DYRK2 ITPR2	1.64e-04	194	95	6	1060_UP
Drug	Viomycin sulfate [37883-00-4]; Down 200; 5.2uM; MCF7; HT_HG-U133A	PTBP3 SUPT20H NBEAL2 DACH1 NFAT5 NPFFR1	1.64e-04	194	95	6	7036_DN
Drug	(S)-(-)-Atenolol [93379-54-5]; Up 200; 15uM; MCF7; HT_HG-U133A	PTBP3 NTRK2 ARHGAP26 TICAM1 TMOD1 SLC25A28	1.69e-04	195	95	6	5325_UP
Drug	PI 540	PIK3CA MTOR	1.71e-04	5	95	2	ctd:C544306
Drug	Iohexol [66108-95-0]; Down 200; 4.8uM; PC3; HT_HG-U133A	PTBP3 SUPT20H BMP2K CASP5 TRIM3 VCL	1.74e-04	196	95	6	4643_DN
Drug	Isoniazid [54-85-3]; Up 200; 29.2uM; HL60; HG-U133A	TRAF6 PIK3CA TSC2 ITGAL NFAT5 DYRK2	1.74e-04	196	95	6	1399_UP
Drug	Zomepirac sodium salt [64092-48-4]; Up 200; 12.8uM; PC3; HT_HG-U133A	SLC24A2 PDK4 NTRK2 ARHGAP26 TRIM3 SMG6	1.74e-04	196	95	6	4479_UP
Drug	daunorubicin HCl; Up 200; 1uM; PC3; HT_HG-U133A	NTRK2 SLC25A28 EPHA4 SMG6 DYRK2 ITPR2	1.74e-04	196	95	6	7511_UP
Drug	Telenzepine dihydrochloride [147416-96-4]; Down 200; 9uM; HL60; HT_HG-U133A	BMP2K MTOR ARHGAP26 NPFFR1 KDM6A DYRK2	1.74e-04	196	95	6	2388_DN
Drug	(d,l)-Tetrahydroberberine [522-97-4]; Down 200; 11.8uM; MCF7; HT_HG-U133A	PHC3 SUPT20H NTRK2 TMOD1 CRTC1 ITPR1	1.74e-04	196	95	6	2818_DN
Drug	Acyclovir [59277-89-3]; Down 200; 17.8uM; PC3; HT_HG-U133A	SUPT20H ARHGAP26 CASP5 NFAT5 TRIM3 VCL	1.74e-04	196	95	6	4683_DN
Drug	Methoxy-8-psoralen [298-81-7]; Down 200; 18.6uM; MCF7; HT_HG-U133A	ADORA2B BMP2K TICAM1 TMOD1 CDK5RAP2 CRTC1	1.74e-04	196	95	6	5007_DN
Drug	Pyrantel tartrate [33401-94-4]; Up 200; 11.2uM; PC3; HT_HG-U133A	SEMA6D DACH1 TMOD1 HERC3 ITGAL TRIM3	1.74e-04	196	95	6	5088_UP
Drug	Midecamycin [35457-80-8]; Down 200; 5uM; PC3; HT_HG-U133A	PTBP3 BMP2K ARHGAP26 ZBTB1 TRIM3 ITPR2	1.74e-04	196	95	6	6745_DN
Drug	SB 203580; Down 200; 1uM; MCF7; HT_HG-U133A	PTBP3 AMPD1 TRAF6 DACH1 TMCO3 TRIM3	1.78e-04	197	95	6	7061_DN
Drug	N6-methyladenosine [1867-73-8]; Down 200; 14.2uM; MCF7; HT_HG-U133A	EVL PHC3 TRAF6 CDK5RAP2 NPFFR1 EPHA4	1.78e-04	197	95	6	5332_DN
Drug	Bumetanide [28395-03-1]; Up 200; 11uM; MCF7; HT_HG-U133A	NTRK2 POT1 TMCO3 ZBTB1 KDM6A TRIM3	1.78e-04	197	95	6	7440_UP
Drug	Eserine sulfate, physostigmine sulfate [64-47-1]; Down 200; 6.2uM; MCF7; HT_HG-U133A	PTBP3 TRAF6 MTOR TMCO3 SLC25A28 KDM6A	1.78e-04	197	95	6	2768_DN
Drug	Chlortetracycline hydrochloride [64-72-2]; Down 200; 7.8uM; MCF7; HT_HG-U133A	PTBP3 BMP2K DACH1 TMOD1 CRTC1 NPFFR1	1.78e-04	197	95	6	1541_DN
Drug	Thonzonium bromide [553-08-2]; Down 200; 6.8uM; MCF7; HT_HG-U133A	PHC3 BMP2K DACH1 ZBTB1 NPFFR1 TRIM3	1.83e-04	198	95	6	5678_DN
Drug	Nizatidine [76963-41-2]; Up 200; 12uM; MCF7; HT_HG-U133A	NTRK2 TICAM1 ZBTB1 NPFFR1 TRIM3 ITPR1	1.83e-04	198	95	6	5406_UP
Drug	Clofilium tosylate [92953-10-1]; Up 200; 7.8uM; PC3; HT_HG-U133A	PTBP3 PDK4 NTRK2 ARHGAP26 DACH1 ITPR1	1.83e-04	198	95	6	4492_UP
Drug	Mefexamide hydrochloride [3413-64-7]; Down 200; 12.6uM; HL60; HG-U133A	EVL TRAF6 RASA1 TRAPPC12 PPFIA1 NUP54	1.83e-04	198	95	6	1438_DN
Drug	haloperidol; Down 200; 10uM; MCF7; HT_HG-U133A	USP36 PTBP3 LAMA5 CDK5RAP2 TMCO3 NFAT5	1.83e-04	198	95	6	7003_DN
Drug	Fenofibrate [49562-28-9]; Down 200; 11uM; MCF7; HT_HG-U133A	MTOR NBEAL2 ARHGAP26 CDK5RAP2 TMCO3 SIK3	1.83e-04	198	95	6	7474_DN
Drug	Tolfenamic acid [13710-19-5]; Down 200; 15.2uM; PC3; HT_HG-U133A	TRAF6 SUPT20H PPFIA1 NPFFR1 KDM6A ITPR1	1.83e-04	198	95	6	2120_DN
Drug	Glycopyrrolate [596-51-0]; Up 200; 10uM; PC3; HT_HG-U133A	ARHGAP26 CASP5 KDM6A TRIM3 SMG6 DYRK2	1.83e-04	198	95	6	7386_UP
Drug	Folinic acid calcium salt [6035-45-6]; Up 200; 7.8uM; PC3; HT_HG-U133A	PTBP3 SLC24A2 NTRK2 CASP5 TMOD1 ITPR2	1.83e-04	198	95	6	3703_UP
Drug	Domperidone maleate; Down 200; 7.4uM; MCF7; HT_HG-U133A	BMP2K DACH1 TMOD1 EIF2AK1 ZBTB1 TRIM3	1.88e-04	199	95	6	5701_DN
Drug	Proparacaine hydrochloride [5875-06-9]; Up 200; 12uM; MCF7; HT_HG-U133A	PDK4 TICAM1 DACH1 CDK5RAP2 CRTC1 ITPR1	1.88e-04	199	95	6	5433_UP
Drug	Benzathine benzylpenicillin [5928-84-7]; Down 200; 4.2uM; MCF7; HT_HG-U133A	SEMA6D BMP2K PDK4 KDM6A TRIM3 SMG6	1.88e-04	199	95	6	4140_DN
Drug	Molindone hydrochloride [15622-65-8]; Down 200; 12.8uM; MCF7; HT_HG-U133A	USP36 PTBP3 PHC3 DACH1 CDK5RAP2 DYRK2	1.88e-04	199	95	6	7337_DN
Drug	Tinidazole [19387-91-8]; Down 200; 16.2uM; MCF7; HT_HG-U133A	NTRK2 TICAM1 DACH1 TRIM3 ITPR1 ITPR2	1.94e-04	200	95	6	3896_DN
Drug	Artemisinin [63968-64-9]; Up 200; 14.2uM; HL60; HG-U133A	PTBP3 TRAPPC12 NBEAL2 CRTC1 NFAT5 DYRK2	1.94e-04	200	95	6	1714_UP
Drug	celecoxib; Down 200; 10uM; MCF7; HG-U133A	TRAF6 SLC24A2 ARHGAP26 HERC3 NFAT5 ZBTB1	1.94e-04	200	95	6	377_DN
Disease	cerebral palsy (implicated_via_orthology)	AGAP7P AGAP4 AGAP6	3.70e-06	10	94	3	DOID:1969 (implicated_via_orthology)
Disease	Hypoxic Brain Damage	ITPR1 ITPR2	1.00e-05	2	94	2	C1140716
Disease	Anoxic Encephalopathy	ITPR1 ITPR2	1.00e-05	2	94	2	C0003132
Disease	Brain Hypoxia	ITPR1 ITPR2	1.00e-05	2	94	2	C1527348
Disease	Anoxia of brain	ITPR1 ITPR2	1.00e-05	2	94	2	C0995195
Disease	Carcinoma of bladder	MTOR KDM6A EPHA4	2.47e-05	18	94	3	C0699885
Disease	Focal Cortical Dysplasia of Taylor, Type IIb	MTOR TSC2	3.01e-05	3	94	2	C1846389
Disease	FOCAL CORTICAL DYSPLASIA OF TAYLOR	MTOR TSC2	3.01e-05	3	94	2	C1846385
Disease	Focal Cortical Dysplasia of Taylor, Type IIa	MTOR TSC2	3.01e-05	3	94	2	C1846386
Disease	Isolated focal cortical dysplasia type II	MTOR TSC2	3.01e-05	3	94	2	cv:C1846385
Disease	FOCAL CORTICAL DYSPLASIA, TYPE II	MTOR TSC2	3.01e-05	3	94	2	607341
Disease	smoking status measurement, Cannabis use, schizophrenia	SEMA6D PHC2 SMG6	1.08e-04	29	94	3	EFO_0006527, EFO_0007585, MONDO_0005090
Disease	Conventional (Clear Cell) Renal Cell Carcinoma	PDXDC1 PIK3CA MTOR TSC2 KDM6A	1.14e-04	148	94	5	C0279702
Disease	entorhinal cortical volume	LZTS1 EPHA4	1.49e-04	6	94	2	EFO_0005092
Disease	Hemimegalencephaly	PIK3CA MTOR	1.49e-04	6	94	2	C0431391
Disease	triacylglycerol 52:4 measurement	DACH1 SIK3 CNOT1	2.07e-04	36	94	3	EFO_0010416
Disease	X-11793--oxidized bilirubin measurement	UGT1A4 UGT1A5	2.78e-04	8	94	2	EFO_0021260
Disease	Succinimide measurement	UGT1A4 UGT1A5	2.78e-04	8	94	2	EFO_0022118
Disease	X-11530 measurement	UGT1A4 UGT1A5	2.78e-04	8	94	2	EFO_0021249
Disease	sulfate of piperine metabolite C16H19NO3 (2) measurement	UGT1A4 UGT1A5	2.78e-04	8	94	2	EFO_0801034
Disease	cholelithiasis, bilirubin measurement	UGT1A4 UGT1A5	2.78e-04	8	94	2	EFO_0004570, EFO_0004799
Disease	X-11522 measurement	UGT1A4 UGT1A5	2.78e-04	8	94	2	EFO_0800696
Disease	X-10458 measurement	UGT1A4 UGT1A5	2.78e-04	8	94	2	EFO_0800692
Disease	X-24849 measurement	UGT1A4 UGT1A5	2.78e-04	8	94	2	EFO_0800909
Disease	membrane-associated progesterone receptor component 1 measurement	UGT1A4 UGT1A5	2.78e-04	8	94	2	EFO_0802740
Disease	X-16946 measurement	UGT1A4 UGT1A5	2.78e-04	8	94	2	EFO_0800766
Disease	renal cell carcinoma	POT1 CRTC1 ITPR2	3.28e-04	42	94	3	EFO_0000681
Disease	X-11442 measurement	UGT1A4 UGT1A5	3.56e-04	9	94	2	EFO_0021236
Disease	X-11441 measurement	UGT1A4 UGT1A5	3.56e-04	9	94	2	EFO_0021235
Disease	circulating cell free DNA measurement	UGT1A4 UGT1A5	3.56e-04	9	94	2	EFO_0004739
Disease	sulfate of piperine metabolite C18H21NO3 (3) measurement	UGT1A4 UGT1A5	3.56e-04	9	94	2	EFO_0801037
Disease	sulfate of piperine metabolite C18H21NO3 (1) measurement	UGT1A4 UGT1A5	3.56e-04	9	94	2	EFO_0801036
Disease	X-11880 measurement	UGT1A4 UGT1A5	3.56e-04	9	94	2	EFO_0800698
Disease	protein-tyrosine kinase 6 measurement	UGT1A4 UGT1A5	3.56e-04	9	94	2	EFO_0020691
Disease	Adult Hepatocellular Carcinoma	PIK3CA TSC2	3.56e-04	9	94	2	C0279607
Disease	testis-specific chromodomain protein Y 1 measurement	UGT1A4 UGT1A5	3.56e-04	9	94	2	EFO_0802127
Disease	bilirubin measurement, response to xenobiotic stimulus	UGT1A4 UGT1A5	3.56e-04	9	94	2	EFO_0004570, GO_0009410
Disease	Thyroid carcinoma	PIK3CA MTOR TSC2	3.77e-04	44	94	3	C0549473
Disease	comparative body size at age 10, self-reported	AMPD1 MCMBP SEMA6D NTRK2 CAMTA1 NPFFR1 SMG6	3.98e-04	420	94	7	EFO_0009819
Disease	bilirubin measurement, response to tenofovir	UGT1A4 UGT1A5	4.44e-04	10	94	2	EFO_0004570, EFO_0009279
Disease	X-21448 measurement	UGT1A4 UGT1A5	4.44e-04	10	94	2	EFO_0800816
Disease	UDP-glucuronosyltransferase 1-6 measurement	UGT1A4 UGT1A5	4.44e-04	10	94	2	EFO_0802185
Disease	X-23974 measurement	UGT1A4 UGT1A5	4.44e-04	10	94	2	EFO_0800867
Disease	Adenocarcinoma of lung (disorder)	PPAN RASA1 PIK3CA NTRK2 EIF2AK1	5.24e-04	206	94	5	C0152013
Disease	pregnenetriol sulfate measurement	UGT1A4 UGT1A5	5.42e-04	11	94	2	EFO_0800586
Disease	plasma N-desmethylclozapine measurement	UGT1A4 UGT1A5	5.42e-04	11	94	2	EFO_0600039
Disease	histidine betaine (hercynine) measurement	UGT1A4 UGT1A5	5.42e-04	11	94	2	EFO_0800972
Disease	X-21796 measurement	UGT1A4 UGT1A5	5.42e-04	11	94	2	EFO_0800825
Disease	insomnia, bilirubin measurement	UGT1A4 UGT1A5	5.42e-04	11	94	2	EFO_0004570, EFO_0004698
Disease	aldosterone measurement	UGT1A4 UGT1A5	5.42e-04	11	94	2	EFO_0010219
Disease	autosomal dominant cerebellar ataxia (implicated_via_orthology)	ITPR1 ITPR2	6.49e-04	12	94	2	DOID:1441 (implicated_via_orthology)
Disease	p-cresol glucuronide measurement	UGT1A4 UGT1A5	6.49e-04	12	94	2	EFO_0800079
Disease	biliverdin measurement	UGT1A4 UGT1A5	6.49e-04	12	94	2	EFO_0021033
Disease	body weight	PDXDC1 PTBP3 SH3RF1 SEMA6D DACH2 SLC24A2 MTOR NTRK2 CRTC1 PHC2 EPHA4 ITPR1	6.63e-04	1261	94	12	EFO_0004338
Disease	kynurenic acid measurement	SEMA6D DYRK2	7.65e-04	13	94	2	EFO_0010506
Disease	pregnenetriol disulfate measurement	UGT1A4 UGT1A5	7.65e-04	13	94	2	EFO_0800587
Disease	retinol dehydrogenase 16 measurement	UGT1A4 UGT1A5	7.65e-04	13	94	2	EFO_0802007
Disease	Malformations of Cortical Development	PIK3CA MTOR	8.91e-04	14	94	2	C1955869
Disease	Adenocarcinoma Of Esophagus	PIK3CA CRTC1	8.91e-04	14	94	2	C0279628
Disease	Cortical Dysplasia	PIK3CA MTOR	8.91e-04	14	94	2	C0431380
Disease	Neoplasm of uncertain or unknown behavior of bladder	MTOR KDM6A	1.03e-03	15	94	2	C0496930
Disease	Benign neoplasm of bladder	MTOR KDM6A	1.03e-03	15	94	2	C0154017
Disease	Carcinoma in situ of bladder	MTOR KDM6A	1.03e-03	15	94	2	C0154091
Disease	attention deficit hyperactivity disorder, substance abuse, antisocial behaviour measurement	IKZF2 SEMA6D DACH1 ELOVL3 HELZ CAMTA1 NFAT5 PHC2 SMG6	1.04e-03	801	94	9	EFO_0003888, EFO_0007052, MONDO_0002491
Disease	S-adenosylhomocysteine measurement	VWA8 CRTC1	1.32e-03	17	94	2	EFO_0010531
Disease	low density lipoprotein cholesterol measurement, body fat percentage	UGT1A4 UGT1A5	1.32e-03	17	94	2	EFO_0004611, EFO_0007800
Disease	X-21441 measurement	UGT1A4 UGT1A5	1.32e-03	17	94	2	EFO_0800814
Disease	sphingosine 1-phosphate measurement	KDM6A ITPR1	1.49e-03	18	94	2	EFO_0800185
Disease	angiopoietin-related protein 1 measurement	UGT1A4 UGT1A5	1.49e-03	18	94	2	EFO_0801382
Disease	autosomal dominant compelling helio-ophthalmic outburst syndrome	SH3RF1 CDK5RAP2 CAMTA1	1.93e-03	77	94	3	EFO_0007887
Disease	red blood cell density measurement	PDXDC1 BMP2K PIK3CA CRTC1 SIK3 CAMTA1 SLC25A28 PHC2 SMG6	1.99e-03	880	94	9	EFO_0007978
Disease	tissue factor measurement	UGT1A4 UGT1A5	2.03e-03	21	94	2	EFO_0010623
Disease	Carcinoma of lung	PIK3CA NTRK2	2.43e-03	23	94	2	C0684249
Disease	West Syndrome	NTRK2 TSC2	2.65e-03	24	94	2	C0037769
Disease	Glioma	PIK3CA NTRK2 POT1	2.73e-03	87	94	3	C0017638
Disease	cholelithiasis	UGT1A4 UGT1A5 NFAT5	2.82e-03	88	94	3	EFO_0004799
Disease	severe acute respiratory syndrome, COVID-19	IKZF2 DACH2 NTRK2 CRTC1 CAMTA1 EIF2AK1	3.10e-03	447	94	6	EFO_0000694, MONDO_0100096
Disease	colon adenocarcinoma (is_implicated_in)	PIK3CA KDM6A	3.10e-03	26	94	2	DOID:234 (is_implicated_in)

Protein segments in the cluster

Peptide	Gene	Start	Entry
MHMNDGRVVSNFILQ	UXS1	266	Q8NBZ7
AMALQSIQNMRGNAH	AGAP4	441	Q96P64
QLMTINMFAVHNSQL	SMG6	941	Q86US8
QMQHMAAINANGLIA	CELF3	236	Q5SZQ8
SLHLMQFQANFQAMT	CAMTA1	671	Q9Y6Y1
MQMNTNQLTSIHADL	COPS3	131	Q9UNS2
AMNMAILLSHANSVV	ADORA2B	271	P29275
AQNKFIMLNLMHETT	AGR3	91	Q8TD06
NLLSLFMMLQNANVT	ABCA13	2021	Q86UQ4
DLQIMNFINLILNHM	ABCA13	2231	Q86UQ4
LAVMGQNLILNMNDH	PGD	11	P52209
FLSSKFQVHQMLNEM	AMPD1	266	P23109
QQMLQQQFLMHSVYQ	BMP2K	511	Q9NSY1
QMNHLSTIANMAAAA	DACH1	456	Q9UI36
AMNQMNHLNTIANMA	DACH2	336	Q96NX9
AMALQSIQNMRGNAH	AGAP6	441	Q5VW22
MVNSFSQDLLMEHIQ	CDK5RAP2	1386	Q96SN8
LSQMNVVNHFRIIAM	RASA1	221	P20936
MNEVMNLAHTFLQNF	ITPR2	1231	Q14571
MGIVNLNIHMNFTHI	SLC2A12	361	Q8TD20
MLMNQHILIFSDSQT	PDK4	171	Q16654
NRHMHTVTNMFILNL	NPFFR1	71	Q9GZQ6
AISVLHEMMQQTFNL	IFNA14	76	P01570
SQNSMQAVMLIHQQL	MDN1	3616	Q9NU22
HNITQGIVLQDSNMM	LZTS1	211	Q9Y250
GILEAVTMQHIFMNN	ITPR1	1276	Q14643
VTMQHIFMNNFQLCS	ITPR1	1281	Q14643
MNSQHSMILEQILNS	HERC3	471	Q15034
EQLESQFVLMQQHQM	KDM6A	496	O15550
LSSVQAMRTQMQQMH	EPHA4	966	P54764
IAVEMTQHLAMTFNQ	IPO7	576	O95373
QDMVSILQLVQNLMH	PDXDC1	56	Q6P996
QDMVSILQLVQNLMH	PDXDC2P	56	Q6P474
MYSHNVVIMNLNNLN	COLEC12	196	Q5KU26
FSNAMLFALNIMNSQ	EVL	101	Q9UI08
QLTMNVPFQAIHFMT	SLC25A28	231	Q96A46
LSQHLEMLQMEQQFQ	KIAA0408	601	Q6ZU52
HTLAMMLQEQLDAIN	PPFIA1	626	Q13136
HHQQMSILQLQLIQM	MSANTD3	201	Q96H12
MKIMVNAALQRQFHS	ITGA11	1101	Q9UKX5
QLEAHIQAAQAMLAM	LAMA5	2606	O15230
IITHQAAMAYNMNLL	HELZ	1226	P42694
LMQSHMMDQAINNAI	IKZF2	311	Q9UKS7
QNSVFQTMVQMQHSG	NFAT5	1001	O94916
MFQSQHSIVAMQSNS	NFAT5	1231	O94916
QQMYAAQQQHLMLHT	PHC3	66	Q8NDX5
IRQHANLFINLFSMM	PIK3CA	991	P42336
QVTDMMIANSHNLIV	PARD6G	231	Q9BYG4
HALLMIAQHTFQNMF	OTOP2	406	Q7RTS6
LNELMSQIRMQNHFG	NUP54	431	Q7Z3B4
IMRNLHDFALQNLMQ	HEATR5A	1966	Q86XA9
HQMFTQTLLNMDQKI	CASP5	126	P51878
QTEAQYHLMLHIQMQ	EIF2AK1	371	Q9BQI3
MVTAMNVSHEVNQLF	ELOVL3	1	Q9HB03
LSHQLEQFNMMENAI	CRTC1	501	Q6UUV9
VFLVDQMHVALNQTM	CFAP70	606	Q5T0N1
MHMALNNQATGLLNL	CCDC188	271	H7C350
NLHLMNLQNMMAEQT	BCL9L	1356	Q86UU0
AMALQSIQNMRGNAH	AGAP7P	441	Q5VUJ5
TMNVIHMLENFTFRN	DYRK2	281	Q92630
NTSVQALMLLFQVMN	CEBPZ	521	Q03701
ALMLLFQVMNSQQTI	CEBPZ	526	Q03701
AQVMMALSNHLNAVE	KLC1	86	Q07866
ASFRLQMTIENMNHL	MCMBP	416	Q9BTE3
IDAFQHMQHFVQTMQ	MTOR	1711	P42345
QSSQATLMLQEHRMF	MROH5	66	Q6ZUA9
QHMTMLNQLYQLQLA	TNRC6C	1146	Q9HCJ0
MLTNLRIFAMSHQTI	GFM2	1	Q969S9
ALKNMQHQNQSLSML	TMCO3	166	Q6UWJ1
SLHNSLMRNSIFQLM	SLC24A2	336	Q9UI40
MLRNFLQGHMVNQES	NBEAL2	956	Q6ZNJ1
MNSENQTMLSLEFHL	POT1	251	Q9NUX5
RQMLQLLMNHLANVA	ARHGAP26	501	Q9UNA1
QMQMQHRTNLMATLS	SIK3	841	Q9Y2K2
VMLSMLTLQHSANNL	HERC2P3	516	Q9BVR0
GHSVALQMMFNTLVN	ITGAL	871	P20701
MIFEVMQNNHIASVT	PHAF1	391	Q9BSU1
HMTGQMTVNQARNAV	SH3RF1	576	Q7Z6J0
LQSLLGNMSHSQLMQ	ADRM1	156	Q16186
LVNMQQYDLHLAQSM	CNOT1	1736	A5YKK6
SQMLHIAQQIAAGMV	NTRK2	651	Q16620
QQMYAAQQQHLMLQT	PHC2	76	Q8IXK0
MVLMNSAFLHLGQNN	TRAPPC12	621	Q8WVT3
IAAILGMHTLMSNQQ	TMOD1	131	P28289
MATMFQNLFPSINVH	PPAN	156	Q9NQ55
MFHENAMLQTENNNL	KIF21A	421	Q7Z4S6
LHQVNQAMMSNLTRQ	TICAM1	466	Q8IUC6
QAQMEQLQVAFGSHM	TICAM1	581	Q8IUC6
HLQENTQSHMRMLAQ	TRAF6	261	Q9Y4K3
HQMAMAAAAAQTAQL	SUPT20H	741	Q8NEM7
QATEMLVHNAQNLMQ	VCL	1086	P18206
NSDHMTFLQRVKNML	UGT1A5	201	P35504
QMADANQAQLAMNHL	PTBP3	401	O95758
MFFMNHQHSTAQLNL	ZBTB1	51	Q9Y2K1
FIQTLSHKQLQAEMM	VWA8	421	A3KMH1
QSGESNQMVHMNVLI	SEMA6D	651	Q8NFY4
NQMVHMNVLITCVFA	SEMA6D	656	Q8NFY4
MLCVMQNHIVQAFAN	USP36	166	Q9P275
VARQMALHANMASQV	TSC2	1711	P49815
LQNNFFISSLMEAMQ	TRIM3	76	O75382
TSRNNSIHAMQMQLY	ZNF114	256	Q8NC26
NSDHMTFLQRVKNML	UGT1A4	201	P22310